NGM · Biotechnology

TRDA (TRDA) Stock

$6.23 +6.89% NGM: TRDA Healthcare

Valuation

MetricValue
Price$6.23
Market Cap$241.91M
P/E Ratio-1.63
P/B Ratio0.72
P/S Ratio39.92
EPS (TTM)$-3.47
52-Week High$16.45
52-Week Low$4.93
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-47.06%
ROA-38.20%
ROCE-50.98%
Gross Margin-624.00%
Operating Margin-624.00%
Net Margin-28.95%
Debt/Equity0.18
Current Ratio12.75

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$129.0M$211.0M$25.0M
Operating Profit$-51.0M$-97.0M$-3.0M$47.0M$-156.0M
Net Profit$-51.0M$-95.0M$-7.0M$66.0M$-144.0M
EPS$-1.60$-2.79$-0.20$1.68$-3.47
Op Margin——-2.5%22.3%-613.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$306.0M$252.0M$469.0M$526.0M$377.0M
Total Liabilities$7.0M$40.0M$227.0M$98.0M$71.0M
Cash$291.0M$45.0M$68.0M$101.0M$90.0M
Borrowings$0$26.0M$68.0M$59.0M$51.0M

Latest News

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study GlobeNewswire · Jun 2, 2026 Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jun 1, 2026 Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile MarketBeat · May 9, 2026 HC Wainwright Downgrades Entrada Therapeutics to Neutral From Buy MT Newswires · May 8, 2026 Entrada’s stock drops as DMD drug’s efficacy falls short Clinical Trials Arena · May 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-51.0M$-94.0M$140.0M$-42.0M$-129.0M
Investing Cash Flow$-9.0M$-152.0M$-144.0M$-31.0M$116.0M
Financing Cash Flow$1.0M$0$2.0M$3.0M$0
Net Cash Flow$252.0M$-246.0M$22.0M$34.0M$-11.0M
Free Cash Flow$-55.0M$-97.0M$134.0M$-45.0M$-130.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-57.47%
Quick Ratio13.90
Interest Coverage—
Return 1Y-5.32%
Return 3Y-64.31%
Return 5Y—

Ownership

Insiders Held12.31%
Institutions Held78.90%
Institutions Float Held89.98%
Institutional HolderSharesReport Date
Baker Bros. Advisors, LP5,072,7302026-03-31
5AM Venture Management, LLC4,056,3792026-03-31
Blackrock Inc.2,358,7932026-03-31
TCG Crossover Management, LLC2,287,5002026-03-31
Merck & Co., Inc.1,739,7682026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About TRDA

TRDA is led by CEO Dipal Doshi, employs 183 people, headquartered in US, publicly traded since 2021.

TRDA stock trades at $6.23 with a market capitalization of $241.91M. The stock is valued at a price-to-earnings (P/E) ratio of -1.63, price-to-book of 0.72, price-to-sales of 39.92. Over the past 52 weeks the stock has ranged between $4.93 and $16.45, and currently trades 62.1% below its 52-week high.

On profitability, TRDA generates a return on equity (ROE) of -47.06%, return on capital employed of -50.98%, an operating margin of -624.00%, a net profit margin of -28.95%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides